IRadimed Corporation (IRMD)

IRadimed Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	17.19	12.83	9.33	1.37	9.63
Depreciation & Amortization	0.77	0.67	1.41	1.34	1.24
Share-Based Compensation	2.19	1.39	1.46	3.96	1.85
Other Operating Activities	-6.68	-4.85	-0.93	-0.85	-2.5
Operating Cash Flow	13.47	10.04	11.26	5.82	10.23
Operating Cash Flow Growth	34.08%	-10.80%	93.52%	-43.15%	38.73%
Capital Expenditures	-8.01	-1.87	-0.74	-0.64	-0.49
Change in Investments	0	0.5	1.39	0.88	3.69
Investing Cash Flow	-8.01	-1.37	0.65	0.25	3.2
Dividends Paid	-13.22	-12.56	0	0	0
Share Issuance / Repurchase	0.18	0.15	0.62	1.73	2.49
Other Financing Activities	-0.61	-0.29	-0.6	-1.21	-0.47
Financing Cash Flow	-13.66	-12.71	0.02	0.52	2.02
Net Cash Flow	-8.2	-4.04	11.93	6.59	15.45
Free Cash Flow	5.46	8.17	10.52	5.18	9.75
Free Cash Flow Growth	-33.18%	-22.33%	102.99%	-46.85%	37.06%
Free Cash Flow Margin	8.32%	15.32%	25.15%	16.33%	25.31%
Free Cash Flow Per Share	0.43	0.65	0.85	0.42	0.86

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).